The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patientsReportar como inadecuado

The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Cancer

, 17:403

Surgical oncology, cancer imaging, and interventional therapeutics


BackgroundBRAF and KRAS mutations are well-established biomarkers in anti-EGFR therapy. However, the prognostic significance of these mutations is still being examined. We determined the prognostic value of BRAF and KRAS mutations in Korean colorectal cancer CRC patients.

MethodsFrom July 2010 to September 2013, 1096 patients who underwent surgery for CRC at Seoul St. Mary’s Hospital were included in the analysis. Resected specimens were examined for BRAF, KRAS, and microsatellite instability MSI status. All data were reviewed retrospectively.

ResultsAmong 1096 patients, 401 36.7% had KRAS mutations and 44 4.0% had BRAF mutations. Of 83 patients, 77 92.8% had microsatellite stable MSS or MSI low MSI-L status while 6 7.2% patients had MSI high MSI-H status. Patients with BRAF mutation demonstrated a worse disease-free survival DFS, HR 1.990, CI 1.080–3.660, P = 0.02 and overall survival OS, HR 3.470, CI 1.900–6.330, P < 0.0001. Regarding KRAS status, no significant difference was noted in DFS P = 0.0548 or OS P = 0.107. Comparing the MSS-MSI-L and MSI-H groups there were no significant differences in either DFS P = 0.294 or OS P = 0.557.

ConclusionsBRAF mutation, rather than KRAS, was a significant prognostic factor in Korean CRC patients at both early and advanced stages. The subgroup analysis for MSI did not show significant differences in clinical outcome. BRAF should be included in future larger prospective biomarker studies on CRC.

KeywordsBRAF mutation KRAS mutation MSI Colorectal cancer AbbreviationsBRAFv-Raf murine sarcoma viral oncogene homolog B1

CIConfidence interval

CRCColorectal cancer

DFSDisease free survival

EGFREpidermal growth factor receptor

FFPEFormalin-fixed paraffin-embedded

KRASv-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog

MAPKMitogen-activated protein kinase

MSIMicrosatellite instability

OSOverall survival

Electronic supplementary materialThe online version of this article doi:10.1186-s12885-017-3381-7 contains supplementary material, which is available to authorized users.

Autor: Daeyoun David Won - Jae Im Lee - In Kyu Lee - Seong-Taek Oh - Eun Sun Jung - Sung Hak Lee


Documentos relacionados